financetom
Business
financetom
/
Business
/
Form 8.3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3
Mar 20, 2026 4:57 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

SAMSON ROCK CAPITAL LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

BRITISH LAND COMPANY PLC ( BRLAF ), THE

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

19/03/2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

YES – LIFE SCIENCE REIT PLC

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

25p ORDINARY

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

(2) Cash-settled derivatives:

 

 

2,146,034

0.21

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

 

 

2,146,034

0.21

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

25p ORDINARY

Equity Swap

Increasing a short position

20,650

361.20 GBp

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(c) Attachments

Class of relevant security:

 

25p ORDINARY

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

(2) Cash-settled derivatives:

 

 

2,146,034

0.21

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

 

 

2,146,034

0.21

0

Class of relevant security:

 

25p ORDINARY

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

(2) Cash-settled derivatives:

 

 

2,146,034

0.21

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

 

 

2,146,034

0.21

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Samson Rock Capital LLP

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Osisko Development Agrees to Divest San Antonio Project to Axo Copper
Osisko Development Agrees to Divest San Antonio Project to Axo Copper
Nov 24, 2025
08:08 AM EST, 11/24/2025 (MT Newswires) -- Osisko Development's ( ODV ) share price rose 1.3% at last look Monday in New York Stock Exchange pre-market trading as the company agreed to sell the San Antonio gold project in Mexico to Axo Copper ( AXOCF ) . The sale is part of Osisko Development's ( ODV ) strategy to focus...
Fairbanks Morse Defense to Acquire Truflo Marine from IMI
Fairbanks Morse Defense to Acquire Truflo Marine from IMI
Nov 24, 2025
Expanded valve and actuator design and manufacturing capabilities further expand FMD offerings and global customer base BELOIT, Wis.--(BUSINESS WIRE)-- Fairbanks Morse Defense (FMD), a portfolio company of Arcline Investment Management, has entered into an agreement with IMI plc, to acquire its Birmingham, UK-based Truflo Marine business. This strategic acquisition significantly enhances the company’s valve design, engineering, and manufacturing capabilities...
What other health conditions are weight-loss drugs being used and tested for?
What other health conditions are weight-loss drugs being used and tested for?
Nov 24, 2025
(Updates to add Novo's Alzheimer trial failure) By Patrick Wingrove Nov 24 (Reuters) - Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer's patients. The results is a blow to hopes that Alzheimer's could open a major new market...
Ocular Therapeutix Begins Phase 3 Registrational Program to Potentially Treat Non-Proliferative Diabetic Retinopathy
Ocular Therapeutix Begins Phase 3 Registrational Program to Potentially Treat Non-Proliferative Diabetic Retinopathy
Nov 24, 2025
08:11 AM EST, 11/24/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) said Monday that it has initiated a phase 3 registrational program for the potential treatment of non-proliferative diabetic retinopathy with Axpaxli. Ocular said that the first patient has been randomized in the phase 3 Helios-3 trial, which will include 930 subjects with moderately severe to severe non-proliferative diabetic...
Copyright 2023-2026 - www.financetom.com All Rights Reserved